Growth hormone in the treatment of short stature in young children with intrauterine growth retardation.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

At baseline, the mean age was 4.5 years, bone age was 3.3 years, height standard deviation score (SDS) was -3.4, height velocity (HV) SDS was -1.6.

Who Took Part

PubMed indexes the participants as young children and children, both men and women.

Patients were enrolled in an open randomized, multicenter trial and allocated to either the treated group (group 1, n = 38) or the control group (group 2, n = 31).

How the Study Was Run

In design terms this was a randomized and multicenter study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

More than one site took part, so the participants came from several places.

Auxologic data were measured every 3 months and bone age was assessed at the start of the study (baseline) and then every 12 months thereafter.

What Was Measured

At baseline, the mean age was 4.5 years, bone age was 3.3 years, height standard deviation score (SDS) was -3.4, height velocity (HV) SDS was -1.6.

Topics PubMed links to this paper include Age Determination by Skeleton, Birth Weight, Body Height, Fetal Growth Retardation, Gestational Age, Growth and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1998 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.